EZH2 and non-small cell lung carcinoma: Moreover, a recent study highlighted the emerging role of prognostic markers to better select the systemic treatment for HCC.43 Quan et al44 found that loss of EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.